reference/23079928

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/23079928

Outgoing Links

Predicate	Object
contentType	Journal Article\|Review
endingPage	457
issn	1750-7448 1750-743X
issueIdentifier	6
pageRange	445-457
publicationName	Immunotherapy
startingPage	445
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_02345d7bcca85c07dd1c414e5d8617b1 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5dfe0b6b2d3de485958eeeea5f0c07b3 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4e0bebdf907fe52526bb1f9c7806514f http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f79ec79ac73d4fc587edae3febe95102
bibliographicCitation	Jiang P, Geng L, Mao Z, Wang Q, Wang W, Jiao M, Yao Y, Chen N, Zhang J, Nan K, Shen Y, Guo H, Jiang L. First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Immunotherapy. 2022 Apr;14(6):445–57. doi: 10.2217/imt-2021-0112.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_910110cfc45f638d27b608c8965f11da http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0eba16f7d4c508aba78890b94d035cf0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3063-4568 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2fcabfdc547c100336bae91c259ceeb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8784902ca147c891fe90ce8a4d247ea3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f2dc29df8a62ff64bc47069cb8b89c0e http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0038-7837 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9780-0845 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3b37ae17843fa11af683d48df89789fb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9f1c53f2b6464d80e53c39854818b12d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_291f343c7838d3e42658aba86f859c6f http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2276-3108 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b857fcc69a567ae50051f805b6acda84
date	2022-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/35259921 https://doi.org/10.2217/imt-2021-0112
isPartOf	https://portal.issn.org/resource/ISSN/1750-743X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/36319 https://portal.issn.org/resource/ISSN/1750-7448
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8352 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168

Total number of triples: 39.